Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 2Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

pembrolizumab 4Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Temozolomide 2Paclitaxel 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2Carboplatin 2temsirolimus 1sugemalimab 1semaglutide 1sacituzumab govitecan 1prednylidene 1pirtobrutinib 1paricalcitol 1pamiparib 1olaparib 1mirdametinib 1gadobutrol 1fludarabine phosphate 1fludarabine 1erdafitinib 1enfortumab vedotin 1dupilumab 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1daratumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × erdafitinib × 30 days × Clear all
NCT06204614 2026-05-18

Drug Screening Using IMD in Bladder Cancer

Brigham and Women's Hospital

Phase EARLY_PHASE1 Enrolling by invitation
18 enrolled
Genitourinary

Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡